Shanghai Medicilon Inc.

On June 11, Keye Life received an implicit approval from the National Medical Products Administration's Center for Drug Evaluation for the clinical trial of its independently developed KY1 small molecule inhibitor IND application.  This IND approval means that clinical trials for DHX33-positive recurrent/refractory advanced malignant tumors can be conducted on schedule in China.  Previously, KY1 had already received implicit approval for clinical trials from both the US FDA and Taiwan. Shanghai Medicilon Inc. (Medicilon), as a partner of Keye Life, provided  efficacy studies  and  safety evaluation services  that comply with both Chinese GLP and U.S. GLP standards for KY1, facilitating its successful dual IND approval in both China and the United States. Having assisted in the approval of 47 dual IND applications in both China and the United States  Medicilon's one-stop service continues to empower the global launch of innovative drugs In the wave of g...

  On March 18, Medicilon Inc. (Medicilon) and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development. Two-way development, move forward together Improve the efficiency of RNA, cell and genetic drug research and development In the exploration of the field of biopharmaceutical, RNA, cell and gene therapy are gradually becoming emerging forces leading the development of the industry with their unique advantages and potential.  These cutting-edge therapies not only open up new path for disease treatment, but also provide new opportunities for biopharmaceutical companies. As a CRO deeply involved in the field of biopharmaceutical preclinical R&D, Medicilon keeps up with the trends and involved in cutting-edge fields such as bi/multi-specific antibodies,  ADCs , mRNA vaccines,  small nucleic acid drugs...

Date:  Sunday, May 14-1-4pm PDT160 E Tasman Dr Address:  160 East Tasman Drive San Jose, CA 95134 United States Organizer:  CBA (Chinese Bioscience Association) Co-organizers:  Medicilon, Q BAY center Media partner: CABS (Chinese-American Bio/Pharmaceutical Society) Gene- and RNA-based therapies show significant promise.  Gene editing aims to treat genetic disease through altering gene expression.  Programmable editing of nucleic acids offers significant therapeutic potential for a wide range of genetic diseases. Gene- and RNA-based therapies need substantial innovation to unlock full potential for patients.  Scaling digital and analytics in discovery and R&D is part of the solution.  Applying artificial intelligence (Al) to R&D for novel therapeutic modalities brings new opportunity. Let's explore the intersection of Al, gene editing, and RNA therapeutics! Dr. Ho Leung Ng the founder of Rise Bio Dr. Ng is the founder of Rise Bio, a startu...